These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1100 related items for PubMed ID: 11753595

  • 1. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 3. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J, Lippl F, Klose G, Schusdziarra V.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1173-9. PubMed ID: 15153170
    [Abstract] [Full Text] [Related]

  • 4. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP, Avenell A, Broom J, Whitehead J.
    Int J Obes Relat Metab Disord; 1997 Jun 01; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G, Mugellini A, Ciccarelli L, Fogari R.
    Clin Ther; 2003 Apr 01; 25(4):1107-22. PubMed ID: 12809960
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 01; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Apr 01; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 8. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A.
    Int J Clin Pharmacol Res; 2002 Apr 01; 22(3-4):85-8. PubMed ID: 12837045
    [Abstract] [Full Text] [Related]

  • 9. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M, European Multicenter Orlistat Study Group.
    Ter Arkh; 2000 Apr 01; 72(8):50-4. PubMed ID: 11019429
    [Abstract] [Full Text] [Related]

  • 10. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
    Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA.
    Int J Obes Relat Metab Disord; 1995 Apr 01; 19(4):221-6. PubMed ID: 7627244
    [Abstract] [Full Text] [Related]

  • 11. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.
    Lancet; 1998 Jul 18; 352(9123):167-72. PubMed ID: 9683204
    [Abstract] [Full Text] [Related]

  • 12. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May 18; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 13. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR.
    Int J Obes Relat Metab Disord; 2003 May 18; 27(5):591-7. PubMed ID: 12704403
    [Abstract] [Full Text] [Related]

  • 14. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct 18; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 15. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov 18; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 16. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan 18; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 17. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N, James WP, Kopelman PG, Lean ME, Williams G.
    Int J Obes Relat Metab Disord; 2000 Mar 18; 24(3):306-13. PubMed ID: 10757623
    [Abstract] [Full Text] [Related]

  • 18. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J.
    JAMA; 2005 Jun 15; 293(23):2873-83. PubMed ID: 15956632
    [Abstract] [Full Text] [Related]

  • 19. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P.
    Int J Obes (Lond); 2007 Mar 15; 31(3):494-9. PubMed ID: 16953261
    [Abstract] [Full Text] [Related]

  • 20. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May 15; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.